> 本文内容由[多巴胺受體D2](https://zh.wikipedia.org/wiki/多巴胺受體D2)转换而来。


**多巴胺受體D<sub>2</sub>**（，簡稱**D2R**），為[轉譯自](https://zh.wikipedia.org/wiki/轉譯 "wikilink") *DRD2* 基因的一種[多巴胺](../Page/多巴胺.md "wikilink")受體蛋白。D2R最早於1975年為所發現，並將其命名為「抗精神疾患性多巴胺受體」（*antipsychotic dopamine receptor*）\[1\]。D2R為所有[抗精神病药物的作用標的](https://zh.wikipedia.org/wiki/抗精神病药 "wikilink")。

## 功能

D2R屬於一種，並會與G<sub>i</sub>結合。G<sub>i</sub>為[G蛋白偶联受体](../Page/G蛋白偶联受体.md "wikilink")的一種亞型，會抑制[腺苷酸环化酶](../Page/腺苷酸环化酶.md "wikilink")的活性\[2\]。

在小鼠模式中，的（NCS-1）會影響D2R在細胞膜的表現量。這項機制會影響[突触可塑性及記憶形成](https://zh.wikipedia.org/wiki/突触可塑性 "wikilink")\[3\]。

在蒼蠅模式中，多巴胺性神經元上的D2R能避免神經元死亡，進而引發類[帕金森氏症](../Page/帕金森氏症.md "wikilink")的症狀\[4\]。

## 同型體

[Alternative splicing](https://zh.wikipedia.org/wiki/選擇性剪接 "wikilink") of this gene results in three transcript variants encoding different s.\[5\]

The long form (**D2Lh**) has the "canonical" sequence and functions as a classic post-[synaptic](../Page/突触.md "wikilink") receptor.\[6\]The short form (**D2Sh**) is pre-synaptic and functions as an  that regulates the levels of dopamine in the synaptic cleft.\[7\][Agonism](../Page/激动剂.md "wikilink") of D2sh receptors inhibits dopamine release; antagonism increases  release.\[8\]A third D2(Longer) form differs from the canonical sequence where 270V is replaced by VVQ.\[9\]

## 基因組

[等位基因變異](https://zh.wikipedia.org/wiki/等位基因 "wikilink")：

  - [A-241G](https://zh.wikipedia.org/wiki/A-241G "wikilink")
  - [C132T](https://zh.wikipedia.org/wiki/C132T "wikilink")、[G423A](https://zh.wikipedia.org/wiki/G423A "wikilink")、[T765C](https://zh.wikipedia.org/wiki/T765C "wikilink")、[C939T](https://zh.wikipedia.org/wiki/C939T "wikilink")、，以及[G1101A](https://zh.wikipedia.org/wiki/G1101A "wikilink")\[10\]
  - [Cys311Ser](https://zh.wikipedia.org/wiki/Cys311Ser "wikilink")
  - \-141C insertion/deletion\[11\]The polymorphisms have been investigated with respect to association with [schizophrenia](../Page/精神分裂症.md "wikilink").\[12\]

Some researchers have previously associated the [polymorphism](../Page/多态性_\(生物学\).md "wikilink") Taq 1A ([rs1800497](https://zh.wikipedia.org/wiki/rs1800497 "wikilink")) to the *DRD2* gene. However, the polymorphism resides in [exon](https://zh.wikipedia.org/wiki/外显子 "wikilink") 8 of the ** gene.\[13\]DRD2 TaqIA polymorphism has been reported to be associated with an increased risk for developing motor fluctuations but not hallucinations in Parkinson's disease.\[14\]\[15\]

## 配體

Most of the older [antipsychotic](https://zh.wikipedia.org/wiki/抗精神病药 "wikilink") drugs such as [chlorpromazine](../Page/氯丙嗪.md "wikilink") and [haloperidol](../Page/氟哌啶醇.md "wikilink") are antagonists for the dopamine D<sub>2</sub> receptor, but are, in general, very unselective, at best selective only for the "D<sub>2</sub>-like family" receptors and so binding to D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub>, and often also to many other receptors such as those for [serotonin](../Page/血清素.md "wikilink") and [histamine](../Page/組織胺.md "wikilink"), resulting in a range of side-effects and making them poor agents for scientific research. In similar manner, older dopamine agonists used for [Parkinson's disease](../Page/帕金森氏症.md "wikilink") such as [bromocriptine](../Page/溴隱亭.md "wikilink") and  are poorly selective for one dopamine receptor over another, and, although most of these agents do act as D<sub>2</sub> agonists, they affect other subtypes as well. Several selective D<sub>2</sub> [ligands](../Page/配體_\(生物化學\).md "wikilink") are, however, now available, and this number is likely to increase as further research progresses.

### 受體致活劑

  - [溴隱亭](../Page/溴隱亭.md "wikilink")（Bromocriptine）：完全受體致活劑

  - （Caberl）

  - [N,N-Propyldihydrexidine](https://zh.wikipedia.org/wiki/N,N-Propyldihydrexidine "wikilink")：D<sub>1</sub>/D<sub>5</sub>受體制活劑的類似物，對節後神經元的D2R親和性比節前神經元的D<sub>2</sub>高。

  - ：同時也是 D<sub>3</sub> 受體致活劑及

  - ：同時也是D<sub>3</sub>、D<sub>4</sub>受體致活劑

  - ：affinity for D<sub>2</sub> \> D<sub>3</sub>

  - ：同時也是D<sub>3</sub>受體致活劑

  - ：完全受體致活劑

  - ：高選擇性完全受體致活劑

  - ：對D<sub>2</sub>的親和性高於其他的多巴胺受體，但同時也是腎上腺素α<sub>2</sub>受體制活劑及5-HT<sub>3</sub>受體拮抗劑。

### 部分受體致活劑

  -
  - [阿立哌唑](../Page/阿立哌唑.md "wikilink")（Aripiprazole，在[美國合法](https://zh.wikipedia.org/wiki/美國 "wikilink")）\[16\]

  - /

  -
  -
  - – Also D<sub>3</sub> antagonist, with good selectivity over other receptors \[17\]

  - [氯胺酮](../Page/氯胺酮.md "wikilink")（Ketamine，同時也為NMDA受體拮抗劑）

  - [LSD](https://zh.wikipedia.org/wiki/D-麦角酸二乙胺 "wikilink") – in vitro, LSD was found to be a partial agonist and potentiates dopamine-mediated prolactin secretion in lactotrophs.\[18\]LSD is also a 5-HT<sub>2A</sub> agonist.

  - [莫达非尼](../Page/莫达非尼.md "wikilink")（Modafinil）

  - (only at the D<sub>2</sub> autoreceptors)

  - ：亦為5-HT<sub>2A</sub>部分受體致活劑，acts as "dopamine stabilizer"

  - ：亦為。

### 受體拮抗劑

  -
  -
  - [Domperidone](../Page/多潘立酮.md "wikilink") – D<sub>2</sub> and D<sub>3</sub> antagonist; does not cross the blood-brain barrier

  -
  -
  - [Hydroxyzine](../Page/羟嗪.md "wikilink") (Vistaril, Atarax)

  -
  - – highly selective D<sub>2</sub> antagonist

  - C<sup>11</sup>  radiolabled – commonly employed in [positron emission tomography](https://zh.wikipedia.org/wiki/正电子发射计算机断层扫描 "wikilink") studies\[19\]

  -
  - SV 293\[20\]

  - [Yohimbine](../Page/育亨宾.md "wikilink")

<!-- end list -->

  - [D<sub>2</sub>sh](https://zh.wikipedia.org/wiki/#Isoforms "wikilink") selective (presynaptic autoreceptors)

<!-- end list -->

  - (low doses)

  -
### 異位調控因子

  - [Homocysteine](../Page/高半胱氨酸.md "wikilink") – 負向\[21\]
  - [PAOPA](https://zh.wikipedia.org/wiki/PAOPA "wikilink")\[22\]
  - SB-269,652 \[23\]\[24\]\[25\]

### Functionally selective ligands

  - 參見參考文獻\[26\]。

## Protein–protein interactions

The dopamine receptor D<sub>2</sub> has been shown to [interact](../Page/蛋白質交互作用.md "wikilink") with ,\[27\]\[28\]and .\[29\]

### Receptor oligomers

The D<sub>2</sub> receptor forms  *[in vivo](https://zh.wikipedia.org/wiki/in_vivo "wikilink")* (in living animals) with other [G protein-coupled receptors](../Page/G蛋白偶联受体.md "wikilink"); these include:\[30\]

  -
  - D<sub>2</sub>–

  - D<sub>2</sub>–

  - [D<sub>2sh</sub>](https://zh.wikipedia.org/wiki/#D2sh "wikilink")–{{\#tag:ref|D2sh–TAAR1 is a presynaptic [heterodimer](../Page/蛋白二聚体.md "wikilink") which involves the relocation of TAAR1 from the intracellular space to D2sh at the [plasma membrane](../Page/细胞膜.md "wikilink"), increased D2sh agonist [binding affinity](../Page/配體_\(生物化學\).md "wikilink"), and [signal transduction](../Page/訊息傳遞_\(生物\).md "wikilink") through the calcium–[PKC](../Page/蛋白激酶C.md "wikilink")– pathway and [G-protein](../Page/G蛋白.md "wikilink") independent [PKB](../Page/蛋白激酶B.md "wikilink")– pathway.\[31\]\[32\]|group="note"}}

The D<sub>2</sub> receptor has been shown to form hetorodimers *[in vitro](https://zh.wikipedia.org/wiki/in_vitro "wikilink")* (and possibly *in vivo*) with ,\[33\],\[34\]and .\[35\]

## 註釋

## 參考文獻

## 外部連結

  -
  -
[Category:G蛋白偶联受体](https://zh.wikipedia.org/wiki/Category:G蛋白偶联受体 "wikilink") [Category:精神藥理學](https://zh.wikipedia.org/wiki/Category:精神藥理學 "wikilink") [Category:注意力不足過動症生物學](https://zh.wikipedia.org/wiki/Category:注意力不足過動症生物學 "wikilink")

1.
2.
3.
4.
5.
6.
7.
8.
9.  [UniProt](../Page/UniProt.md "wikilink")
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.